If investors were to read over the history of Critical Outcome Technologies, Inc., they’d think it came out of a movie. A little-known and chronically underfunded Canadian company conquering the odds to potentially cure cancer through a novel approach the rest of the scientific community had long given up on. It’s your classic underdog story.
Our continuing efforts to advance our lead cancer drug, COTI-2, were featured in an article on Equities.com, called "A Critical Time for One of Biotech’s Underdog Success Stories." As the article highlights, what makes COTI-2 special "is the focus on mutated or inactive p53 protein."
Welcome to our blog. We use this space to provide more insight into the latest developments in our business as well as recent events in the field of drug discovery and development.